Elisabetta Vulpis Selected Research

Elisabetta Vulpis Research Topics

12	Neoplasms (Cancer) 05/2023 - 07/2015
9	Multiple Myeloma 05/2023 - 07/2015
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2022
1	Leukemia 01/2022
1	COVID-19 01/2021
1	Inflammation (Inflammations) 01/2020
1	Virus Diseases (Viral Diseases) 09/2019
1	Fabry Disease (Fabry's Disease) 11/2015
1	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 11/2015

9	LigandsIBA 05/2023 - 07/2015
6	micaIBA 05/2023 - 09/2015
3	Peptide Hydrolases (Proteases)FDA Link 05/2023 - 01/2020
3	CytokinesIBA 01/2020 - 12/2016
2	Metalloproteases (Metalloproteinases)IBA 01/2020 - 01/2016
1	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2023
1	MicroRNAs (MicroRNA)IBA 04/2023
1	Biomarkers (Surrogate Marker)IBA 05/2022
1	Immune Checkpoint InhibitorsIBA 05/2022
1	Signaling Lymphocytic Activation Molecule Family Member 1IBA 01/2022
1	Programmed Cell Death 1 ReceptorIBA 01/2022
1	VaccinesIBA 01/2021
1	DisintegrinsIBA 01/2020
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2020
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 09/2019
1	RNA (Ribonucleic Acid)IBA 09/2019
1	triphosphoric acid (triphosphate)IBA 09/2019
1	Interleukin-12 (IL 12)IBA 09/2019
1	CaspasesIBA 09/2019
1	Interleukin-15 (Interleukin 15)IBA 01/2018
1	Melphalan (Alkeran)FDA LinkGeneric 01/2017
1	NF-kappa B (NF-kB)IBA 01/2017
1	Proteins (Proteins, Gene)FDA Link 12/2016
1	3-nitrotyrosineIBA 11/2015
1	GalactosidasesIBA 11/2015
1	globotriaosylceramide (globotriosylceramide)IBA 11/2015
1	Immunomodulating AgentsIBA 09/2015